Standardization of outcome measures in clinical trials of pharmacological treatment for abdominal aortic aneurysm

Automatic measurement of maximal diameter of abdominal aortic aneurysm on computed tomography angiography using artificial intelligence

INTRODUCTION

The treatment of abdominal aortic aneurysm (AAA) relies on surgical repair and the indication mainly depends on its size evaluated by the maximal diameter (Dmax). The aim of this study was to evaluate a new automatic method based on artificial intelligence (AI) to measure the Dmax on computed tomography angiography (CTA).

METHODS

A fully automatic segmentation of the vascular system was performed using a hybrid method combining expert system with supervised deep learning (DL). The aorta centreline was extracted from the segmented aorta and the aortic diameters were automatically calculated. Results were compared to manual segmentation performed by two human operators.

RESULTS

The median absolute error between the two human operators was 1.2 mm (IQR 0.5- 1.9). The automatic method using the DL algorithm demonstrated correlation with the human segmentation, with a median absolute error of 0.8 (0.5- 4.2) mm and a coefficient correlation of 0.91 (p<0.001).

CONCLUSION

Although validation in larger cohorts is required, this method brings perspectives to develop new tools to standardize and automate the measurement of AAA Dmax in order to help clinicians in the decision-making process.

Background and Proposed Design for a Metformin Abdominal Aortic Aneurysm Suppression Trial

Abdominal aortic aneurysm (AAA) may lead to rupture and death if left untreated. While endovascular or surgical repair is generally recommended for AAA greater than 5–5.5 cm, the vast majority of aneurysms detected by screening modalities are smaller than this threshold. Once discovered, there would be a significant potential benefit in suppressing the growth of these small aneurysms in order to obviate the need for repair and mitigate rupture risk. Patients with diabetes, in particular those taking the oral hypoglycaemic medication metformin, have been shown to have lower incidence, growth rate, and rupture risk of AAA. Metformin therefore represents a widely available, non-toxic, potential inhibitor of AAA growth, but thus far no prospective clinical studies have evaluated this. Here, we present the background, rationale, and design for a randomised, double-blind, placebo-controlled clinical trial of metformin for growth suppression in patients with small AAA.

Metformin treatment status and abdominal aortic aneurysm disease progression

OBJECTIVE

In population-based studies performed on multiple continents during the past two decades, diabetes mellitus has been negatively associated with the prevalence and progression of abdominal aortic aneurysm (AAA) disease. We investigated the possibility that metformin, the primary oral hypoglycemic agent in use worldwide, may influence the progression of AAA disease.

METHODS

Preoperative AAA patients with diabetes were identified from an institutional database. After tabulation of individual cardiovascular and demographic risk factors and prescription drug regimens, odds ratios for categorical influences on annual AAA enlargement were calculated through nominal logistical regression. Experimental AAA modeling experiments were subsequently performed in normoglycemic mice to validate the database-derived observations as well as to suggest potential mechanisms of metformin-mediated aneurysm suppression.

RESULTS

Fifty-eight patients met criteria for study inclusion. Of 11 distinct classes of medication considered, only metformin use was negatively associated with AAA enlargement. This association remained significant after controlling for gender, age, cigarette smoking status, and obesity. The median enlargement rate in AAA patients not taking oral diabetic medication was 1.5 mm/y; by nominal logistic regression, metformin, hyperlipidemia, and age ≥70 years were associated with below-median enlargement, whereas sulfonylurea therapy, initial aortic diameter ≥40 mm, and statin use were associated with above-median enlargement. In experimental modeling, metformin dramatically suppressed the formation and progression, with medial elastin and smooth muscle preservation and reduced aortic mural macrophage, CD8 T cell, and neovessel density.

CONCLUSIONS

Epidemiologic evidence of AAA suppression in diabetes may be attributable to concurrent therapy with the oral hypoglycemic agent metformin.

A framework for creating standardized outcome measures for patient registries

Aim: Our objectives were to create a conceptual framework for development of standard outcome measures and to design and pilot test a tool for displaying outcome measures. Materials & methods: Information on outcome measures used in registries was gathered through stakeholder discussions, which informed the development of the outcome measurement framework and the related tool. Results: The outcome measurement framework is a conceptual model for how information relevant to evaluating patient outcomes may be defined and collected in a standard way for a broad range of health areas. The related tool facilitates collecting, displaying and searching for information on outcome measures. Conclusion: The model developed through this process offers a framework that can be used to define outcome measures in a standard way across medical conditions.